Gestational diabetes mellitus prediction? A unique fatty acid profile study

Gestational diabetes mellitus (GDM) arises from insulin insensitivity and is associated with adverse perinatal outcomes and potential long-term metabolic effects in offspring. Prevalence varies globally (about 5% in the UK; up to 33.5% in South East Asia). Known risk factors predict GDM with ~75% accuracy, but improved markers are needed. Obesity underlies most cases via chronic inflammation and altered adipokines. Polyunsaturated fatty acids (PUFA), especially n-3, have anti-inflammatory properties and may improve insulin sensitivity and adiponectin. Fatty acids derive from diet and hepatic synthesis via elongase/desaturase enzymes; dietary composition, genetics, micronutrients, and microbiota affect conversion. Given DHA (n-3) and ArA (n-6) roles in CNS and immune function, and the potential of fatty acid ratios (e.g., ArA:DHA) as inflammatory markers linked to insulin resistance, the study asks whether women at risk of GDM exhibit a unique erythrocyte fatty acid profile and whether such profiling could aid early prediction of GDM.

Background literature highlights: (1) GDM’s prevalence and risk profile, with obesity as a major driver. (2) PUFA, particularly n-3 fatty acids, are anti-inflammatory and can enhance insulin sensitivity and adiponectin. (3) Hepatic conversion from parent fats (LA for n-6, ALA for n-3) depends on elongase/desaturase enzymes; dietary LA intake can suppress ALA→DHA conversion by up to 40%. (4) DHA and ArA are critical for CNS and immune function. (5) Ratios such as ArA:DHA correlate with pro-inflammatory adipokines (IL-6, TNF-α) and may reflect insulin resistance; absolute fatty acid values vary widely among individuals, supporting the use of ratios. These points motivate examining specific fatty acid ratios as potential markers distinguishing GDM from normal pregnancy.

Design: Double-blind randomized placebo-controlled trial (FOSS study). Recruitment at Chelsea and Westminster Hospital (London) antenatal clinic at booking. Participants: N=300 pregnant women. Randomized to a normal healthy control (NHC) group (n=50) and three high-risk groups (n=250), including a GDM subgroup (n=50). This report focuses on the GDM group (n=50) versus NHC. High-risk inclusion criteria: Age >35, South East Asian or North African descent, previous GDM, family history of type II diabetes mellitus, BMI >30, or prior macrosomic infant. Sampling and laboratory analyses: At recruitment, prior to any supplementation, blood samples were collected. Erythrocyte total lipids were extracted using the Folch method; fatty acid composition assessed by capillary gas chromatography. Results expressed as mean percentage of total erythrocyte fatty acids. GDM diagnosis followed NICE criteria. Ethics and registration: Written informed consent obtained. Ethics approval: East London Research Ethics Committee (07/H0704/99). Trial registration: ISRCTN24068733. Statistical analysis: Continuous variables compared using unpaired two-tailed Student’s t test (normality assessed via frequency distributions and histograms). Categorical variables compared with chi-squared tests. SPSS v22 used. Statistical significance defined as p<0.05.

Demographics:

• GDM women were heavier and shorter with higher BMI than NHC: weight 78.71±17.78 kg vs 68.40±11.07 kg (p=0.001); height 162.54±7.75 cm vs 165.84±6.53 cm (p=0.026); BMI 29.73±5.52 vs 25.00±3.91 (p<0.001). Maternal age not different (32.40±6.51 vs 33.31±5.14, p=0.449).
• Socioeconomic differences: GDM group had lower socioeconomic status, lower educational attainment, and higher unemployment (significant chi-squared p-values for maternal ethnicity p=0.049, marital status p=0.008, education p=0.010, occupation p=0.004). Paternal sociodemographic variables did not differ significantly.

Fatty acid profiles (erythrocyte, mean % of total FA unless ratio specified; GDM vs NHC):

• Palmitic acid: 24.61±1.38 vs 23.89±1.39 (p=0.014) [elevated in GDM]
• Linoleic acid (LA): 14.22±2.20 vs 13.31±1.67 (p=0.028) [elevated]
• Eicosadienoic acid (EDA): 0.03±0.02 vs 0.04±0.02 (p=0.017) [lower]
• Adrenic acid (AdA): 2.10±0.40 vs 1.91±0.38 (p=0.021) [elevated]
• Docosapentaenoic acid (DPA, n-3): 1.59±0.37 vs 1.81±0.32 (p=0.003) [lower]
• Docosahexaenoic acid (DHA, n-3): 4.35±1.14 vs 4.92±0.91 (p=0.010) [lower]
• Ratios indicating altered metabolism/inflammation: • LA/ArA: 1.18±0.32 vs 1.06±0.21 (p=0.035) [elevated] • LA/DHA: 3.55±1.30 vs 2.80±0.65 (p=0.001) [elevated] • ArA/DHA: 3.01±0.72 vs 2.68±0.51 (p=0.012) [elevated] • n-6/n-3: 4.69±1.23 vs 3.92±0.73 (p<0.001) [elevated] • LC n-6/LC n-3: 2.66±0.65 vs 2.30±0.45 (p=0.003) [elevated] • MUFA/n-3: 2.88±0.93 vs 2.44±0.66 (p=0.011) [elevated] • DHA/EPA: 8.92±4.23 vs 7.25±2.45 (p=0.022) [elevated] • ArA/DPA: 16.75±2.27 vs 17.70±1.89 (p=0.031) [lower]

Summary pattern: GDM women exhibit elevated n-6 fatty acids and ratios (n-6:n-3, LA:DHA, LA:ArA, ArA:DHA), higher saturated fat (palmitic acid), and depressed n-3 fatty acids (DPA, DHA), suggesting an abnormal pattern of sequential n-6 metabolism and potential desaturase/elongase enzyme insufficiency. These findings align with the abstract results (elevated n-6 vs n-3; distorted LA–ArA relationship; depressed DHA).

The study addresses whether women at risk of GDM have a distinct erythrocyte fatty acid signature relative to healthy controls. The findings demonstrate higher n-6 relative to n-3 fatty acids, elevated palmitic acid, and multiple increased ratios (LA:DHA, LA:ArA, ArA:DHA, n-6:n-3, LC n-6:LC n-3), alongside reduced n-3 DPA and DHA. Considering the high inter-individual variability of absolute fatty acids, the consistent ratio shifts suggest specific metabolic alterations in GDM. Mechanistically, the pattern indicates potential insufficiency or underutilization of hepatic desaturase and elongase enzymes critical to converting parent fats (LA, ALA) into longer-chain PUFA. Notably, the elevated LA but relatively lower downstream metabolites (e.g., indicated by LA/ArA elevation) and an undulating precursor–product pattern (e.g., AdA elevated but DPA reduced) imply impaired Δ6/Δ5-desaturase activity in early pregnancy among women who develop GDM. This is consistent with known suppression of desaturase activity in insulin resistance/diabetes and contrasts with pregnancy-associated upregulation of these enzymes in healthy states. Dietary factors (high n-6, low n-3 intake), increased saturated fat, and micronutrient influences (e.g., zinc status) may contribute. The altered fatty acid milieu could exacerbate inflammation (higher ArA:DHA ratio correlating with IL-6/TNF-α) and reduce anti-inflammatory, pro-resolving mediator synthesis (from DHA), potentially worsening insulin sensitivity. These results support the utility of fatty acid profiling—particularly specific ratios—as early biomarkers for GDM risk stratification and suggest that targeted nutritional strategies might modify risk if applied early.

Pregnant women at risk of GDM show a distinctive erythrocyte fatty acid profile at antenatal booking, characterized by elevated n-6 fatty acids and ratios (e.g., LA:DHA, n-6:n-3), reduced n-3 fatty acids (DPA, DHA), and an abnormal sequential n-6 metabolic pattern indicative of impaired desaturase/elongase activity. These findings provide a basis for developing clinically applicable early prediction tools for GDM and point toward potential targeted interventions (e.g., optimizing n-3 intake, addressing saturated fat excess, and relevant micronutrient status). Future research should validate predictive models in diverse populations, elucidate enzymatic and microbiome mechanisms, and test fatty acid-targeted preventive interventions.